The FDA plans to mine data submitted by patients on the site PatientsLikeMe.
The FDA, in an attempt to gather post-marketing data directly from the source, is planning to access data submitted on the patient-networking website PatientsLikeMe. The hope is to collect data that patients submit on drug-use experiences, symptoms, and hospitalizations.
The project is currently in its exploratory phase. “We’re hoping we can find information on the impact of adverse events on patients’ day-to-day lives,” said Gerald Dal Pan, director of the Office of Surveillance and Epidemiology at the FDA, in a statement.
Read more on Bloomberg News: http://bloom.bg/1Laqub8
The Supreme Court seems likely to reject a challenge to the abortion pill mifepristone; the FDA is inspecting far fewer pharmaceutical companies conducting clinical research; AstraZeneca has sued to block an Arkansas law that it said would unlawfully expand the 340B program to include for profit-pharmacy chains.
Read More